Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrödinger, Inc. reports developments tied to its computational platform for molecular discovery, which is licensed to biotechnology, pharmaceutical, industrial and academic customers for drug development and materials design. Company updates commonly cover Software segment performance, hosted and license-server delivery, annual contract value, and the role of software revenue in the business.
News also addresses Schrödinger's Drug Discovery segment, including collaborative and internal programs, together with clinical or regulatory disclosures when applicable. Recurring corporate items include quarterly and annual financial results, investor conference participation, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), shareholder voting matters, governance changes and capital-structure disclosures.
Schrödinger (Nasdaq: SDGR) announced its participation in the Truist Securities Life Sciences AI Symposium on March 1, 2022. Karen Akinsanya, Ph.D., will join a panel discussing technology-enabled drug discovery at 10:10 a.m. ET. An on-demand workshop titled “Transforming Molecular Design of Novel Drug,” hosted by Ramy Farid, Ph.D., will also be available. Access details for the panel and workshop can be found in the investors section of Schrödinger's website. Founded in 1990, Schrödinger employs over 650 individuals and focuses on innovative drug discovery through its physics-based software platform.
Schrödinger, Inc. (Nasdaq: SDGR) reported a strong fourth quarter with software revenue of $38.6 million, a 55% increase from Q4 2020. For the full year 2021, total revenue reached $137.9 million, up 28% year-over-year, with software revenue of $113.2 million, increasing 22%. The company provided a positive outlook for 2022, anticipating total revenue between $161 million and $181 million, and software revenue between $126 million and $136 million. Additionally, Schrödinger announced strategic goals including a Phase 1 clinical study of its MALT1 inhibitor.
Schrödinger, Inc. (Nasdaq: SDGR) announced the grant of non-statutory stock options totaling 32,425 shares to 17 newly hired employees as part of its 2021 Inducement Equity Incentive Plan on February 14, 2022. These options, which have an exercise price of $26.99 per share, will vest over four years. The grants aim to attract talent, complying with Nasdaq Listing Rule 5635(c)(4). Schrödinger leverages its physics-based software platform for drug discovery and materials development, engaging with clients across over 70 countries.
Schrödinger (Nasdaq: SDGR) will release its fourth quarter and full year 2021 financial results on February 24, 2022, after market close. A conference call will take place at 4:30 p.m. ET. Interested parties can access the live webcast on Schrödinger’s website. The company focuses on a physics-based software platform that enhances therapeutic and materials discovery, used by various organizations globally. With over 500 employees and clients in more than 70 countries, Schrödinger aims to lower costs and speed up drug development.
Schrödinger (Nasdaq: SDGR) will present a company overview at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on February 16, 2022, at 1:00 p.m. ET. The live presentation will be accessible via the company's website under the 'News & Events' section and will be archived for about seven days.
Founded in 1990, Schrödinger's software platform accelerates drug and materials discovery, engaging with over 500 employees and customers in over 70 countries.
On January 16, 2022, Schrödinger, Inc. (Nasdaq: SDGR) granted stock options to purchase 80,675 shares of common stock to 80 new employees, primarily in India. This action was part of the company’s 2021 Inducement Equity Incentive Plan and was approved by its compensation committee. The exercise price is set at $30.69 per share, matching the closing price on January 14, 2022. The options have a ten-year term and vest over four years. Schrödinger focuses on transforming therapeutic and material discovery through its innovative software platform.
Schrödinger, Inc. (Nasdaq: SDGR) has completed a $6 million all-cash acquisition of XTAL BioStructures, Inc. on January 14, 2022. This strategic acquisition enhances Schrödinger's capabilities in structure-based drug discovery by integrating structural biology services, including biophysical methods and X-ray crystallography. By bringing these services in-house, Schrödinger aims to improve its drug discovery programs through access to high-quality protein structures and bolster its product offerings with validated computational structures.
Schrödinger (Nasdaq: SDGR) will participate in a fireside chat at the H.C. Wainwright BioConnect Conference, with a pre-recorded presentation set for January 10, 2022, at 11:00 a.m. ET. The webcast will be available on-demand on Schrödinger’s website under "News & Events" and archived for seven days. The company is known for its physics-based software platform that accelerates the discovery of therapeutics and materials. Founded in 1990, Schrödinger employs over 500 staff and collaborates globally.
Schrödinger (Nasdaq: SDGR) announces the retirement of CFO Joel Lebowitz, effective February 28, 2022. Lebowitz, who played a key role in the company’s transition to public status and financial growth, will assist in the search for his successor. CEO Ramy Farid commended his contributions, stating that Schrödinger is well-capitalized and positioned for future success. The company reaffirms its full-year 2021 financial guidance, previously announced on November 10, 2021.
Schrödinger, Inc. (Nasdaq: SDGR) granted non-statutory stock options to 14 new employees totaling 42,850 shares on December 16, 2021, as part of its 2021 Inducement Equity Incentive Plan. The options have an exercise price of $35.04 per share, reflecting the closing stock price on that date. Each option vests over four years, with 25% vesting after the first year and the remainder monthly over the next three years. Schrödinger leverages its physics-based software platform for drug and material discovery, serving clients in over 70 countries.